Multihance and Valcyte drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Multihance (gadobenate dimeglumine) and Valcyte (valganciclovir hydrochloride). Common drug interactions include arthralgia among females and nephrogenic systemic fibrosis among males.

The phase IV clinical study analyzes what interactions people have when they take Multihance and Valcyte. It is created by eHealthMe based on reports of 34 people who take the same drugs from the FDA, and is updated regularly.

What is Multihance?

Multihance has active ingredients of gadobenate dimeglumine. eHealthMe is studying from 5,786 Multihance users. Check the latest studies of Multihance.

What is Valcyte?

Valcyte has active ingredients of valganciclovir hydrochloride. It is often used in cmv - immunocompromised host. eHealthMe is studying from 6,409 Valcyte users. Check the latest studies of Valcyte.

On Jul, 15, 2026

34 people who take Multihance and Valcyte together, and have interactions are studied.

Multihance and Valcyte drug interactions.

What are the common drug interactions of Multihance and Valcyte, by gender? *:

female:

Arthralgia (joint pain)
Emotional distress
Fibrosis (formation of excess fibrous connective tissue in an organ or tissue)
General physical health deterioration (weak health status)
Injury
Mobility decreased (ability to move is reduced)
Oedema (fluid collection in tissue)
Rash erythematous (redness of the skin)
Joint contracture (a permanent shortening of a muscle or joint)
Pruritus (severe itching of the skin)

male:

Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Mobility decreased (ability to move is reduced)
Skin lesion
Anhedonia (inability to experience pleasure from activities usually found enjoyable)
General physical health deterioration (weak health status)
Skin hypertrophy (skin cells enlarges)
Skin induration (an abnormally hard spot or area on the skin)
Extremity contracture (permanent shortening of a muscle or joint of arms and legs)
Myalgia (muscle pain)
Joint range of motion decreased (disease of joint movement)

What are the common drug interactions of Multihance and Valcyte, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Anxiety
Arthralgia (joint pain)
Burning sensation
Dysstasia (difficulty in standing)
Emotional distress
Erythema (redness of the skin)
Injury
Joint range of motion decreased (disease of joint movement)
Joint stiffness
Limb discomfort (discomfort in leg)

30-39:

Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Pain
Anhedonia (inability to experience pleasure from activities usually found enjoyable)
Anxiety
General physical health deterioration (weak health status)
Scar
Mobility decreased (ability to move is reduced)
Burning sensation
Emotional distress
Fibrosis (formation of excess fibrous connective tissue in an organ or tissue)

40-49:

Dry skin
Dyspnoea (difficult or laboured respiration)
Excoriation (to tear or wear off the skin of)
Extremity contracture (permanent shortening of a muscle or joint of arms and legs)
Granuloma (a small area of inflammation due to tissue injury)
Hypoaesthesia (reduced sense of touch or sensation)
Insomnia (sleeplessness)
Lichenification (thickening and hardening of the skin)
Lung disorder (lung disease)
Muscle fibrosis (fibrous muscle)

50-59:

Joint range of motion decreased (disease of joint movement)
Musculoskeletal stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves)
Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Pain
Skin induration (an abnormally hard spot or area on the skin)
Skin tightness
Erythema (redness of the skin)
Scar
Skin hyperpigmentation (disorders affect the colour of your skin)
Pruritus (severe itching of the skin)

60+:

Breast fibrosis (the thickening and scarring of connective tissue, usually as a result of injury in breast)
Exercise tolerance decreased
Pain in extremity
Peau d'orange (orange peel skin)
Rash macular (small, flat red spots)
Skin discolouration (change of skin colour)
Skin fibrosis (fibrous tissue formation on skin)
Skin hypertrophy (skin cells enlarges)
Skin induration (an abnormally hard spot or area on the skin)
Skin plaque (red, scaly patches to appear on the skin)

What are the existing conditions these people have? *

Nuclear Magnetic Resonance Imaging Abdominal: 9 people, 26.47%
Nuclear Magnetic Resonance Imaging Brain: 6 people, 17.65%
Computerised Tomogram Abdomen: 5 people, 14.71%
Bipolar Disorder (mood disorder): 3 people, 8.82%
Anaemia (lack of blood): 3 people, 8.82%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 2 people, 5.88%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 5.88%
Diabetes: 2 people, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Multihance and Valcyte?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously